Cationically Enframed High-Density Aromatic Peptides for Cardiolipin Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective compounds that target strong bases to cardiolipin in mitochondrial membranes, which are crucial for stabilizing mitochondrial membrane potential and preventing cellular oxidative stress, contributing to various debilitating disorders.
Innovation Solution
Development of cationic and aromatic peptides with specific amino acid configurations that bind selectively to cardiolipin, stabilizing mitochondrial membranes and enhancing proton trapping, thereby improving mitochondrial function and reducing oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional mitochondrial compounds are used, then mitochondrial function can be supported, but the available options are limited and effectiveness is insufficient
Solution Approach 1:
The patent modifies the chemical parameters of mitochondrial compounds by creating peptides with specific amino acid compositions (combining cationic and aromatic residues), specific sequences, and defined structural characteristics. This systematic parameter change generates a new class of compounds with enhanced effectiveness and expanded therapeutic options for mitochondrial dysfunction.
Solution Approach 2:
The invention creates composite peptide structures that combine multiple functional amino acid residues (cationic residues for membrane interaction and aromatic residues for structural stability and proton trapping) into unified molecular entities. This composite approach produces compounds with synergistic effects that address multiple mitochondrial function aspects simultaneously.
2Reliability
If compounds targeting cardiolipin are developed, then mitochondrial membrane potential can be stabilized, but no effective compounds currently exist
Solution Approach 1:
The patent segments the peptide structure into distinct functional modules: cationic amino acid residues that interact with cardiolipin phosphate groups and aromatic amino acid residues that provide structural framework and proton trapping capability. This segmentation allows each module to be optimized independently while achieving the overall goal of cardiolipin targeting and membrane potential stabilization.
Solution Approach 2:
The peptide compounds act as intermediary agents between external therapeutic intervention and the cardiolipin-proton trapping system in mitochondrial membranes. The cationic residues mediate the interaction with negatively charged cardiolipin, while the aromatic residues mediate proton trapping, thereby stabilizing membrane potential through this intermediary peptide-carboxylipin complex.
3Productivity
If peptide structure is optimized for cardiolipin binding, then proton trapping is enhanced, but peptide design complexity increases
Solution Approach 1:
The patent employs known amino acid residue patterns and structural motifs from existing functional peptides as templates, copying and adapting successful design elements. By using established cationic and aromatic residue combinations that have demonstrated effectiveness in similar contexts, the invention reduces design complexity while maintaining high proton trapping efficiency.
Solution Approach 2:
The invention optimizes peptide design by systematically adjusting parameters such as residue composition ratios, peptide length, and sequence arrangement. These parameter changes are made within constrained ranges that balance proton trapping efficiency with synthetic feasibility, avoiding overly complex designs while maximizing functional performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively stabilize mitochondrial membrane potential, reduce oxidative stress, and promote cell survival in conditions of serum starvation and mitochondrial dysfunction, demonstrating significant protection of retinal ganglion cells and other tissues.
Implementation Method 1
The peptide has a cationic D-amino acid at the N-terminus and a cationic D-amino acid at the C-terminus... bind selectively to cardiolipin, stabilizing mitochondrial membranes
Implementation Method 2
Proton trapping on the outer leaflet of the inner mitochondrial membrane of mitochondrial cristae could be controlled by cardiolipin (CL) when the local pH is above 8... the net number of the aromatic residues is greater than or equal to the net number of positive residues
Data Source
AI summary
A method of treating mitochondria dysfunction-associated discloses by administering a biotinylated peptide with r residues (from 4-10) that are either cationic or aromatic. The peptide has a cationic D-amino acid at the N-terminus and a cationic D-amino acid at the C-terminus. The net number of positive residues (np), is 2≤np≤r−2. The net number of the aromatic residues is greater than or equal to the net number of positive residues.